Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Aug;29(4):279–287. doi: 10.1007/BF00199216

Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy

Sigla Shoval 1, Rachel Ophir 1, Shlomo Ben-Efraim 1,✉
PMCID: PMC11038020  PMID: 2787695

Abstract

Mice cured from large MOPC-315 tumors by a single dose of melphalan, 7.5 mg/kg, were examined for up to 60 days after the drug treatment (71 days after the tumor inoculation) for their ability to respond to mitogenic stimulation, specific and nonspecific antigenic stimulation and for their susceptibility to inoculation with an unrelated tumor, L10 lymphoma. The response of spleen cells from cured mice to mitogenic stimulation by phytohemagglutinin or concanavalin A was slightly depressed at an early stage after the drug treatment. The allogeneic response against C57BL spleen cells and the antibody response against sheep red blood cells (SRBC) of spleen cells from cured mice remained below normal levels during the whole observation period. The deficiency in response to antigenic stimulation was found to be due to impairment in T-cell function. Cured mice were also deficient in their response to SRBC immunization (antibody and delayed-type hypersensitivity responses) and were more susceptible to inoculation with an unrelated tumor, L10 lymphoma, than normal, noninoculated mice. On the other hand, spleen cells of cured mice developed a highly specific cytotoxic response against target MOPC-315 tumor cells and the cured mice were resistant to challenge with an otherwise highly tumorigenic dose of MOPC-315. Thus, cured mice remained deficient for a long period of time in their response to MOPC-315-unrelated antigens but, at the same time, they showed a potent specific antitumor immunity potential in vivo and in vitro.

Keywords: Spleen Cell, Antitumor Immunity, Antigenic Stimulation, Plasmacytomas, Mitogenic Stimulation

Footnotes

The contribution of S. Shoval is in partial fullfillment of a PhD Thesis

References

  • 1.Ben-Efraim S, Bocian RC, Mokyr MB, Dray S. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol Immunother. 1983;15:101. doi: 10.1007/BF00199699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Ben-Efraim S, Halperin D, Reuben C, Dar O, Weiss D. Effects of methanol extract residue (MER) tubercle bacillus fraction on the production of antibodies in vitro. II. Effects on macrophage and lymphocyte populations. Cellular Immunol. 1984;86:33. doi: 10.1016/0008-8749(84)90356-3. [DOI] [PubMed] [Google Scholar]
  • 3.Berko R, Seissman K, Colvin M, Bocian RC, Ben-Efraim S, Dray S. Tumoricidal and immunomodulatory activities of drugs and implications for therapy of mice bearing a late stage MOPC-315 plasmacytoma. Int J Immunopharmacol. 1988;10:825. doi: 10.1016/0192-0561(88)90006-9. [DOI] [PubMed] [Google Scholar]
  • 4.Bocian RC, Ben-Efraim S, Dray S, Mokyr MB. Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother. 1984;18:41. doi: 10.1007/BF00205398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bocian RC, Dray S, Ben-Efraim S, Mokyr MB. Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor. Cancer Immunol Immunother. 1985;20:61. doi: 10.1007/BF00199775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Brus I, Brent J, Hollander VP. Lymphocyte defect in plasmacytoma-bearing mice. Br J Cancer. 1978;37:545. doi: 10.1038/bjc.1978.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Carlson FJ, Smith F. Effect of plasma cell tumor on antibody production by mouse spleen cells. Proc Soc Exp Biol Med. 1968;127:212. doi: 10.3181/00379727-127-32658. [DOI] [PubMed] [Google Scholar]
  • 8.Cunningham AJ, Szenberg A. Further improvements in the plaque techniques for detecting single antibodies forming cells. Immunology. 1968;14:599. [PMC free article] [PubMed] [Google Scholar]
  • 9.Dray S, Bocian RC, Ben-Efraim S, Mokyr MB. Mechanism of melphalan-mediated modulation of antitumor immune potential of tumor-bearer lymphoid cells. Cancer Treat Symp. 1985;1:3. [Google Scholar]
  • 10.Eipert EF, Adorini L, Condero J. A miniaturized in vitro diffusion culture system. J Immunol Methods. 1978;22:283. doi: 10.1016/0022-1759(78)90036-4. [DOI] [PubMed] [Google Scholar]
  • 11.Fahey JL, Humphrey JH. Effects of transplantable plasma cell tumors on antibody responses in mice. Immunology. 1962;5:110. [PMC free article] [PubMed] [Google Scholar]
  • 12.Fenton MR, Havas HF. The effect of plasmacytoma on serum immunoglobulin levels of Balb/c mice. J Immunol. 1975;114:793. [PubMed] [Google Scholar]
  • 13.Julius MY, Simpson R, Herzenberg LA. A rapid method for the isolation of functional thymus derived murine lymphocytes. Eur J Immunol. 1973;3:645. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  • 14.Katzman YA. Myeloma induced immunosuppression: a multistep mechanism. J Immunol. 1978;121:1405. [PubMed] [Google Scholar]
  • 15.Lagrange PH, Mackanes GB, Miller TE. Influence of dose and route of antigen injection on the immunological induction of T cells. J Exp Med. 1974;139:528. doi: 10.1084/jem.139.3.528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Lowy I, Bussard AE. A simple method for the removal of antibody forming cells from whole spleen cell population. J Immunol Methods. 1974;5:107. doi: 10.1016/0022-1759(74)90053-2. [DOI] [PubMed] [Google Scholar]
  • 17.Mokyr MB, Braun DP, Usher D, Reiter H, Dray S. The development of in vitro and in vivo antitumor cytotoxicity in non-cytotoxic, MOPC-315 tumor-bearer, spleen cells “educated” in vitro with MOPC-315 tumor cells. Cancer Immunol Immunother. 1978;4:143. [Google Scholar]
  • 18.Mokyr MB, Hengst JCD, Prezepiorka D, Dray S. Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization. Cancer Res. 1979;39:3928. [PubMed] [Google Scholar]
  • 19.Mokyr MB, Braun DP, Dray S. Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation. Cancer Res. 1979;39:785. [PubMed] [Google Scholar]
  • 20.Nahas F, Ophir R, Ben Efraim S. Effect of melphalan administration on the activity of natural killer and natural cytotoxic spleen cells of normal and tumor-bearing mice. Immunol Lett. 1985;10:333. doi: 10.1016/0165-2478(85)90128-2. [DOI] [PubMed] [Google Scholar]
  • 21.Ophir R, Ben-Efraim S. Effect of melphalan in vitro on induction of murine suppressor T cells by Con A. Cancer Immunol Immunother. 1985;20:209. doi: 10.1007/BF00205578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Oppenheim JJ, Rosenstreich DL. Lymphocyte transformation: utilization of automatic harvesters. In: Bloom BR, David JR, editors. In vivo methods in cell-mediated and tumor immunity. New York, San Francisco, London: Academic Press; 1976. p. 593. [Google Scholar]
  • 23.Sagi O, Witz IP, Ramot B, Sahar E, Duer D. Late immune and haemopoietic functions in plasmacytoma-bearing mice cured by melphalan. Br J Cancer. 1988;57:271. doi: 10.1038/bjc.1988.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Schwarzbard Z, Ophir R, Gotlieb-Stematsky T, Ben-Efraim S. Importance of the concomitant presence of palpable MOPC-315 tumor in stimulation of splenocytes by C-type MOPC-315 virus in vitro. Eur J Cancer Clin Oncol. 1985;21:1069. doi: 10.1016/0277-5379(85)90293-7. [DOI] [PubMed] [Google Scholar]
  • 25.Takesue BY, Bartik MM, Mokyr MB. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes coexpressing the Lyt2 and the L3T4 antigens. Int J Immunopharmacol. 1987;9:705. doi: 10.1016/0192-0561(87)90042-7. [DOI] [PubMed] [Google Scholar]
  • 26.Ye QW, Mokyr MB, Pyle JM, Dray S. Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother. 1984;16:162. doi: 10.1007/BF00205423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zolla-Pazner S, Fleit S, Kolb JP. Regulation of the immune response by tumors. In: Waters H, editor. The handbook of cancer immunology, vol 2. New York: Garland Publishing; 1978. p. 225. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES